Komori
Share Issuance and Disposal4882Perseus Proteomics Inc.Pharmaceuticals

Notice Regarding the Issuance of Stock Compensation-Type Stock Options (Share Acquisition Rights)

The Company resolved to issue 1,237 stock acquisition rights as equity compensation stock options to 3 executive officers and 31 employees. If all rights are exercised, 123,700 common shares will be delivered.

Worth reading
48Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
123700
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of share subscription rights as stock compensation stock options

Who receives how much

123,700 common shares (1,237 stock acquisition rights, 100 shares per right)

3 of the Company's executive officers (excluding those elected as directors of the Company)28,000 shares (280 stock acquisition rights)
31 employees of the Company95,700 shares (957 stock acquisition rights)

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

Not applicable (the stock acquisition rights are issued without consideration)
Terms of the stock acquisition rights
Exercise price
¥1 per share. Adjustment provisions and floor: Not disclosed
Exercise period
Start Date 1 May 2027 / End date 30 April 2036 (if the final day is not a bank business day, the preceding bank business day)
Number of Stock Acquisition Rights
Total issued: 1,237 rights; unexercised balance: Not disclosed
Reason for acquisition without consideration
If approval or other authorization is obtained at a shareholders' meeting for a corporate reorganization or other such matter, or if the rights become unexercisable before exercise, the Company may acquire all or the relevant portion of these stock acquisition rights without consideration.
Conditions on transfer restrictions

Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.

Conditions for lifting transfer restrictions
One-third will vest on the first anniversary of the allotment date, another one-third on the second anniversary, and the remaining balance on the third anniversary. If the holder ceases to be a director, audit & supervisory board member or employee, vesting after that point will cease, except in certain cases.
Categories and Number of Persons Covered
Category The Company's executive officers (excluding those elected as directors of the Company) / Number of Employees 3 / Number allocated 280 rights (28,000 shares), Category The Company's employees / Number of Employees 31 / Number allocated 957 rights (95,700 shares)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of share subscription rights as stock compensation stock options
Number of shares to be issued or disposed of123,700 common shares (1,237 stock acquisition rights, 100 shares per right)
Issue price and disposal priceNot applicable (the stock acquisition rights are issued without consideration)
Intended allotteeName 3 of the Company's executive officers (excluding those elected as directors of the Company) / Number of Shares 28,000 shares (280 stock acquisition rights), Name 31 employees of the Company / Number of Shares 95,700 shares (957 stock acquisition rights)
Exercise price¥1 per share. Adjustment provisions and floor: Not disclosed
Exercise periodStart Date 1 May 2027 / End date 30 April 2036 (if the final day is not a bank business day, the preceding bank business day)
Number of Stock Acquisition RightsTotal issued: 1,237 rights; unexercised balance: Not disclosed
Conditions for lifting transfer restrictionsOne-third will vest on the first anniversary of the allotment date, another one-third on the second anniversary, and the remaining balance on the third anniversary. If the holder ceases to be a director, audit & supervisory board member or employee, vesting after that point will cease, except in certain cases.
Reason for acquisition without considerationIf approval or other authorization is obtained at a shareholders' meeting for a corporate reorganization or other such matter, or if the rights become unexercisable before exercise, the Company may acquire all or the relevant portion of these stock acquisition rights without consideration.
Categories and Number of Persons CoveredCategory The Company's executive officers (excluding those elected as directors of the Company) / Number of Employees 3 / Number allocated 280 rights (28,000 shares), Category The Company's employees / Number of Employees 31 / Number allocated 957 rights (95,700 shares)
Items this document does not state (18)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To ensure that the executive officers and employees share with shareholders not only the benefits of a rise in the share price but also the risks of a decline, thereby increasing their motivation and morale to contribute to improved performance and enhanced corporate value over the medium to long term.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Issuance of Stock Compensation-Type Stock Options (Share Acquisition Rights) | Perseus Proteomics Inc. (4882) timely disclosure | Komori